CD86 and neoplasm: However, the combination of two SNPs, namely rs1129055 of CD86 gene and rs231775 of the CTLA4 gene caught our attention because CD86 and CTLA4 engage in a receptor-ligand interaction that inhibit anti-tumor immune response [56].